Daniele Piomelli

picture of Daniele  Piomelli

Professor, Anatomy & Neurobiology
School of Medicine
Louise Turner Arnold Chair in Neurosciences

Joint Appointment, Biological Chemistry
School of Medicine
Joint Appointment, Pharmacology
School of Medicine
Director, Institute for the Study of Cannabis

Ph.D., Columbia University, New York, 1988, Pharmacology
Pharm.D., University of Naples, Italy, 1982
Doctor of Medicine, honoris causa, Goethe University, Frankfurt, Germany, 2012

Phone: (949) 824-7080
Fax: (949) 824-6305
Email: piomelli@uci.edu

University of California, Irvine
Department of Anatomy & Neurobiology
Gillespie NRF 3101, 3216
Mail Code: 1275
Irvine, CA 92697
Research Interests
cellular pharmacology, neuropharmacology
Academic Distinctions
Jun 1988 National Alliance for Research on Schizophrenia and
Depression (NARSAD) Young Investigator Award
Jun 1990 National Alliance for Research on Schizophrenia and
Depression (NARSAD) Young Investigator Award
May 1999 National Alliance for Research on Schizophrenia and
Depression (NARSAD) Independent Investigator Award
May 2001 ad hoc member; NIH Centers Review Committee
May 2001 ad hoc member; NIH Program Projects Review Committee
Jun 2001 ad hoc member; NIAAA Board of Counselors
Jun 2001 Course Director; International School of Immunology,
“Ruggero Ceppellini”
Sep 2001 NIH Independent Investigator Award
May 2002 Grass Traveling Fellowship
Jul 2002 Chancellor Scholar; University of California, Irvine
Jul 2002 International Kemali Foundation Prize in Neurosciences
Oct 2003 Member of the NIDA Delegation to the Office of Drug Control
Policy (ONDCP)
May 2005 National Alliance for Research on Schizophrenia and Depression
(NARSAD) Distinguished Investigator Award
May 2007 Member of the National Advisory Council on Drug Abuse
Apr 2008 Chair, NIDA Scientific Director Review, Baltimore, MD
May 2009 National Alliance for Research on Schizophrenia and Depression
(NARSAD) Distinguished Investigator Award
Sep 2010 National Institute on Drug Abuse (NIDA) Avant-Garde Award for
Innovative Medication Development Research
Sep 2012 European Lipid Science Award, European Federation of Lipid
Nov 2012 Honorary Medical Doctoral degree, Goethe University, Frankfurt,
Dec 2015 Fellow, American College of Neuropsychopharmacology
Sep 2017 The Mechoulam Award, The International Cannabinoid Research
Sep 2017 The Ester Fride Award for Basic Research, The International
Association for Cannabinoid Medicines
Research Abstract
Dr. Piomelli was trained in neuroscience and pharmacology. Research in his lab is focused on the function of lipid-derived messengers, with particular emphasis on the endogenous cannabinoids anandamide and 2-arachidonoylglycerol. Current research efforts converge on three areas: formation and deactivation of anandamide and 2-arachidonylglycerol; physiological roles of the endogenous cannabinoid system; development of therapeutic agents that target anandamide and 2-arachidonylglycerol metabolism.
Primary neural cell cultures and state-of-the-art analytical techniques such as liquid chromatography/mass-spectrometry are used to investigate formation and deactivation of anandamide and 2-arachidonoylglycerol in brain cells. Protein purification and cloning approaches are employed to characterize the molecular mechanisms underlying these processes. Cellular pharmacology and medicinal chemistry, in collaboration with leading international labs, are used to identify pharmacological agents that interfere with various aspects of endogenous cannabinoid function, and their therapeutic potential is explored in vitro and in vivo.
Available Technologies
Selected Publications:

N. Stella, P. Schweitzer and D. Piomelli, 1997. A second endogenous cannabinoid that modulates long-term potentiation. Nature 388, 773-778.

M. Beltramo, N. Stella, A. Calignano, S.Y. Lin, A. Makryiannis and D. Piomelli, 1997. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 277, 1094-1097.

A. Calignano, G. La Rana, A. Giuffrida and D. Piomelli, 1998. Control of pain initiation by endogenous cannabinoids. Nature 394, 277-281.

A. Giuffrida, L. Parsons, T.M. Kerr, F. Rodríguez de Fonseca, M. Navarro and D. Piomelli, 1999. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci 2, 358-363.

D. Piomelli, M. Beltramo, S. Glasnapp, S.Y. Lin, A. Goutopoulos, Xiang-Qun Xie and A. Makriyannis, 1999. Structural determinants for recognition and translocation by the anandamide transporter. Proc Natl Acad Sci U S A 96, 5802-5807.

I. Katona, F. Désarnaud, A. Giuffrida, G. La Rana, K. Mackie, T.F. Freund and D. Piomelli, 2000. Bidirectional control of airway responsiveness by endogenous cannabinoids. Nature 408, 96-101.

F. Rodríguez de Fonseca, M. Navarro, R. Gómez, L. Escuredo, F. Nava, J. Fu, E. Murillo-Rodríguez, A. Giuffrida, J. LoVerme, S. Gaetani, S. Kathuria, C. Gall and D. Piomelli, 2001. An anorexic lipid mediator regulated by feeding. Nature 414, 209-212.

T. Dinh, D. Carpenter, F.M. Leslie, T.F. Freund, I. Katona, S.L. Sensi, S. Kathuria and D. Piomelli, 2002. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci U S A 99, 10819-10824.

S. Kathuria, S. Gaetani, D. Fegley, F. Valiño, A. Duranti, A. Tontini, M. Mor, G. Tarzia, G. La Rana, A. Calignano, A. Giustino, M. Tattoli, M. Palmery, V. Cuomo and D. Piomelli, 2003. Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9, 76-81.

T.F. Freund, I. Katona and D. Piomelli, 2003. The role of endogenous cannabinoids in synaptic signaling. Physiol Rev 83, 1017-1066.

J. Fu, S. Gaetani, F. Oveisi, J. LoVerme, A. Serrano, F. Rodríguez de Fonseca, A. Rosengarth, H. Luecke, B. Di Giacomo, G. Tarzia and D. Piomelli, 2003. Oleylethanolamide regulates feeding and body weight through activation of PPAR-?. Nature 425, 90-93.

D. Piomelli, 2003. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 4, 873-884.

D. Fegley, S. Kathuria, R. Mercier, C. Li, A. Goutopoulos, A. Makriyannis and D. Piomelli, 2004. Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis resistant inhibitor AM1172. Pro Natl Acad Sci U S A 101, 8756-8761.

A.G. Hohmann, R.L. Suplita II, N.M. Bolton, M.H. Neely, D. Fegley, R. Mangieri, J. Krey, J.M. Walker, P.V. Holmes, J.D. Crystal, A. Duranti, A. Tontini, M. Mor, G. Tarzia and D. Piomelli, 2005. An endocannabinoid mechanism for stress-induced analgesia. Nature 435, 1108-1112.

J. Makara, M. Mor, D. Fegley, S.I. Szabo, S. Kathuria, G. Astarita, A. Duranti, A. Tontini, G. Tarzia, S. Rivara, T. Freund and D. Piomelli, 2005. Selective inhibition of 2-AG hydrolysis enhances endocannabinoid signaling in hippocampus. Nat Neurosci 8, 1139-1141.

M.D. Van Sickle, M. Duncan, P. J. Kingsley, A. Mouihate, P. Urbani, K. Mackie, N. Stella, A. Makriyannis, D. Piomelli, J. S. Davison, L.J. Marnett, V. Di Marzo, Q.J. Pittman, K. D. Patel and K.A. Sharkey, 2005. Identification and Characterization of Brainstem Cannabinoid CB2 Receptors. Science 310, 329-332.

G. Gobbi, F.R. Bambico, R. Mangieri, M. Bortolato, P. Campolongo, M. Solinas, T. Cassano, M.G. Morgese, G. Debonnel, A. Duranti, A. Tontini, G. Tarzia, M. Mor, V. Trezza, S.R. Goldberg, V. Cuomo, and D. Piomelli, 2005. Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci U S A 102, 18620-18625.

D. Piomelli, G. Astarita and R. Rapaka, 2007. A neuroscientist’s guide to lipidomics. Nat Rev Neurosci, 8, 743-754.

G.J. Schwartz, J. Fu, G. Astarita, X. Li, S. Gaetani, P. Campolongo, V. Cuomo and D. Piomelli, 2008. The lipid messenger OEA links dietary fat intake to satiety. Cell Metab 8, 281-288. PMCID: PMC2572640.

P. Campolongo, B. Roozendaal, V. Trezza, V. Cuomo, G. Astarita, J. Fu, J.L. McGaugh and D. Piomelli, 2009. Fat-induced satiety factor oleoylethanolamide enhances memory consolidation. Proc Natl Acad Sci U.S.A., 106, 8027-8031.
2017-2019 UCI Research Seed Funding, “Investing to Develop Center-Scale Multidisciplinary Convergence Research Programs” (P.I., D. Piomelli)
2017-2019 NIH-STTR- Anteana Therapeutics, Inc., 2R42DA033683; “Peripheral FAAH as a target for novel analgesics” (P.I., D. Piomelli)
2017-2018 Jackson Foundation for the Advancement of Military Med (Henry M), DOD Uniformed Services University of the Health Sciences, HU0001-15-2-0067/3689; “Evaluation of the Safety and Pharmacokinetics of the FAAH Inhibitor URB597” (P.I., D. Piomelli)
2016-2018 NIA- R21AG052336: “A Protective role for 2-AG in age-dependent cognitive impairment”. (P.I., D. Piomelli)
2016-2018 NIDA-Cutting-Edge Basic Research Awards (CEBRA) 1R21DA041776; Lipidomics analysis of identified single neurons in the adult rodent brain. (P.I., D. Piomelli)
Professional Societies
Member, American Association for the Advancement of Science (AAAS)
Member, American College of Neuropsychopharmacology (ACNP)
Member, American Physiological Society (APS)
Member, American Society for Biochemistry and Molecular Biolology (ASBMB)
Member, American Society for Pharmacology and Experimental Therapeutics (ASPET)
Member, International Cannabinoid Research Society (ICRS)
Member, Society of Biological Psychiatry (SBP)
Member, Società Italiana di Farmacologia (SIF)
Member, Society for Neuroscience (SFN)
Graduate Programs
Pharmacological Sciences

Interdepartmental Neuroscience Program

Medicinal Chemistry and Pharmacology

Cellular and Molecular Biosciences

Last updated